By a News Reporter-Staff News Editor at Biotech Week — Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma exacerbations (CAE) compared to placebo in two pivotal Phase III studies in patients with inadequately controlled moderate to severe asthma with elevated levels of blood eosinophils (see also Pharmaceutical Companies).
In both trials, reslizumab treatment showed both clinically relevant and statistically significant reductions in the frequency of CAE compared to placebo (50% and 60% respectively, p European Respiratory Society Congress, Sept 6-10). The combination of an effect on clinically important exacerbations and on improvements and preservation of lung function suggest that reslizumab may be a uniquely differentiated treatment for patients with moderate to severe asthma with elevated levels of blood eosinophils.
“The consistent results from these duplicate Phase III trials demonstrating substantial reductions in asthma exacerbations are impressive,” said Professor Mario Castro, Washington University School of Medicine, Division of Pulmonary and Critical Care Medicine and lead investigator. “They support the potential of targeted anti-IL-5 therapy with reslizumab in patients with moderate-severe persistent asthma and elevated blood eosinophils who are at risk for asthma exacerbations and are uncontrolled by standard asthma therapies.”
This initial set of results shows the adverse event profile of reslizumab was comparable to placebo in both trials. The incidence of common AEs (> 5%) was consistent with those seen in a moderate to severe asthma population, the most frequent being upper respiratory tract infections, asthma and headache. Further analyses of additional efficacy and safety data are ongoing.
“These pivotal Phase III study results are striking. Asthma that is inadequately controlled by current standard of care therapy continues to present a serious problem for patients, physicians and healthcare systems. The success of these studies gives us confidence that we may have a valuable potential new treatment option for asthma patients, with elevated levels of blood eosinophils, who are at risk of exacerbation,” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. “We plan to submit applications for approval in the US, Europe and other regions as soon as possible.”
The results announced provide a strong foundation for investigation of additional indications, such as COPD with elevated eosinophils. The ongoing development of a subcutaneous formulation will further strengthen the franchise and is expected to be submitted for approval in the second half of 2017.
These new data are from two global Phase III 12-month, randomized, double-blind, placebo-controlled, parallel-group studies, evaluating the efficacy and safety of intravenously administered reslizumab (3.0 mg/kg) once every four weeks, compared to placebo in asthma patients (12-75 years of age with elevated blood eosinophils) that are inadequately controlled by standard of care therapy.
The two pivotal Phase III studies involved 953 patients across 232 medical centers worldwide including the US, EU and the Far East. These studies are part of the Phase III BREATH program that evaluated the safety and efficacy of reslizumab treatment in four separate Phase III trials involving more than 1700 adolescent and adult asthma patients with elevated eosinophils, whose symptoms were inadequately controlled with inhaled corticosteroids with or without another controller medication.
Increased levels of blood eosinophils have been shown to correlate with future risk and severity of asthma exacerbations. IL-5 is an important element in the growth and activity of eosinophils and blocking its activity has now been shown to reduce asthma exacerbation. Uncontrolled asthma, associated with elevated eosinophils, impacts a large number of patients. It is a major challenge for both clinicians and patients and constitutes a significant burden on healthcare systems: It is estimated that the market for severe asthma biotech drugs could exceed $7.5 billion a year in the United States and Europe alone.
Detailed analyses of the data are ongoing and full results will be submitted for presentation to a future scientific meeting and for publication in a peer reviewed journal. About Reslizumab Reslizumab is an investigational humanized monoclonal antibody (mAb) against interleukin-5 (IL-5). IL-5 has been shown to play a crucial role in the maturation, growth and chemotaxis (movement) of eosinophils, inflammatory white blood cells implicated in a number of allergic diseases. About the Studies Study NCT012870391 was a Phase III, 12-month, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in 489 patients with eosinophilic asthma. Its primary objective was to demonstrate the efficacy of reslizumab, at a dose of 3 mg/kg administered IV every 4 weeks, as assessed by the reduction in frequency of clinical asthma exacerbations (CAEs). Principal investigator – Professor Mario Castro, MD, Washington University School of Medicine, Division of Pulmonary and Critical Care Medicine. Study was conducted in 128 study centers including – USA, Australia, Germany, France, New Zealand, Chile, Colombia, Israel, Sweden, Denmark, Russia, Hungary, Czech Republic, Poland, South Africa, Thailand and more.
Study NCT01285323 was a Phase III, 12-month, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of reslizumab treatment (3 mg/kg administered IV every 4 weeks) in the reduction of clinical asthma exacerbations in 464 patients (12-75 years of age) with eosinophilic asthma whose symptoms are inadequately controlled with inhaled corticosteroids. Principal investigator – Dr. Stephanie Korn, Head of Clinical Research Pulmonology, Asthma and COPD clinic, Mainz University Hospital in Germany.
Keywords for this news article include: Asthma, Bronchial Diseases, Clinical Trials and Studies, Critical Care Medicine, Immune System Diseases, Obstructive Lung Diseases, Patient Care, Pharmaceutical Companies, Pharmaceutical Company, Respiratory Hypersensitivity, Respiratory Tract Diseases, Teva Pharmaceutical Industries Ltd., Therapy.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC